bioMérieux, a world leader in the field of in vitro diagnostics, has submitted the BIOFIRE® SPOTFIRE® Respiratory/Sore Throat (R/ST) Panel to U.S. Food and Drug Administration (FDA) for a dual 510(k) clearance and CLIA1-waiver. This panel is already CE-marked (IVDD).
Swipe to discover more
Consolidated sales amounted to €1,770 million in first-half 2023, a robust growth like-for-like of 8.3% from €1,658 million in the prior year.
Antibiotics are crucial for treating infections that cause sepsis in newborns, but antibiotic overuse or misuse can also have negative effects. Find out why diagnostics and antimicrobial stewardship are critical for guiding treatment in the NICU.
bioMérieux and JMI Laboratories (JMI) are announcing a six-year partnership to undertake collaborative projects evaluating the performance and increasing potential of rapid and innovative microbiology diagnostics as important tools in the battle against AMR.
?qlt=85&ts=1670238196189&dpr=off)
